Clinical Research Directory

Inclusion Criteria: The main inclusion criteria include but are not limited to the following: * Has clinical diagnosis of HF with preserved ejection fraction on optimized guideline-directed medical therapy * Has CpcPH confirmed by right-heart catheterization * Has NYHA FC II or III Exclusion Criteria: The main exclusion criteria include but are not limited to the following: * Has a diagnosis of PH in World Health Organization Group 1, 3, 4, or 5 * Has CV comorbidities: * History of surgical or transcatheter correction of mitral or aortic stenosis or regurgitation within 12 months before Screening * More than one valve replacement or repair (mechanical or bioprosthetic), or anticipated valve replacement or repair during the study * History of serious, life-threatening, or hemodynamically significant arrhythmia, long corrected QT interval syndrome, or Brugada syndrome * History of hypertrophic cardiomyopathy, infiltrative cardiomyopathy (including, but not limited to, cardiac amyloidosis), dilated cardiomyopathy, arrhythmogenic ventricular cardiomyopathy, or restrictive cardiomyopathy * History or evidence of chronic liver disease * Has a current diagnosis of end-stage renal disease * History of organ transplantation (except corneal transplant) or bone marrow transplantation ≤5 years before Screening or has a life expectancy of \<12 months * History of malignancy ≤5 years before Screening, with the exception of fully excised or treated basal cell carcinoma, cervical carcinoma in situ, or ≤2 squamous cell carcinomas of the skin * Has any noncardiopulmonary condition or acute/chronic impairment(s) (other than dyspnea) that limits their ability to perform the 6-minute walk test * Has moderate or severe obstructive sleep apnea * Has a body mass index ≥50 kg/m\^2 * Has been treated with any approved pulmonary arterial hypertension-specific medications within 30 days of Randomization * Has background medication with the following agents: sodium-glucose cotransporter-2 inhibitor, renin-angiotensin-aldosterone system inhibitors, mineralocorticoid receptor antagonists, diuretics, and beta-blockers, that is not a stable dose for ≥30 days before Randomization